US FDA has no adverse observations after scan of Dr Reddy's Hyderabad R&D unit
The United States Food & Drug Administration (FDA) did a routine Good Manufacturing Practice (GMP) inspection at Dr Reddy's integrated product development organisation in Bachupally, Hyderabad. Shares of Dr Reddy's Laboratories Ltd ended at ₹6,552.50, up by ₹45.70, or 0.70%, on the BSE.